Figure S3.

Proliferation of Lgr6-Expressing Cells following Targeted Injury of Lgr6⁺ Cells, Related to Figure 4

(A) Representative confocal images showing the specific ablation of airway smooth muscle cells (ASMCs) marked by Lgr6 at 2 days post PBS (upper panels) or DT (lower panels) administration: Tdtomato (red), α-SMA (yellow), GFP (green), and DAPI (blue). Arrowhead, vascular smooth muscle cells.

(B) Graphs to show the mean percentage of lineage-labeled Lgr6⁺ cells (Tom⁺GFP⁺, red bar), non-labeled Lgr6-expressing cells (Tom^–GFP⁺, green bar), and Lgr6-negative cells (Tom^–GFP^–, yellow bar) that express α-SMA at indicated time points after PBS or DT treatment.

(C) Representative confocal images showing proliferation of club cells after PBS (upper panels) or DT (lower panels) administration in Lgr6-CreERT2;R26-Tom;R26-iDTR mice: Tdtomato (for Lgr6, red), Ki67 (white), CCSP (cyan) and DAPI (blue). Arrow, Ki67⁺ club cells.

(D) Representative confocal images (left) and graph (right) showing proliferation of Lgr6-expressing cells (Tom^–GFP⁺) that were not tagged at 7days after DT administration (left): Tdtomato (red), Ki67 (white), GFP (green), and DAPI (blue). Arrow, Ki67⁺ Lgr6-expressing cells. Graphs to show the mean percentage of non-labeled Lgr6-expressing cells that express Ki67 at indicated time points after PBS (black bars) or DT (blue bars) treatment. Data represent the mean of percentage from three individual mice per group (at least five sections). Error bars indicate standard deviation (^∗∗p < 0.005). Scale bars, 100um.